ProfileGDS5678 / 1453048_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 62% 61% 68% 70% 51% 62% 65% 67% 59% 63% 66% 67% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.737962
GSM967853U87-EV human glioblastoma xenograft - Control 23.7219162
GSM967854U87-EV human glioblastoma xenograft - Control 33.6479961
GSM967855U87-EV human glioblastoma xenograft - Control 44.2077968
GSM967856U87-EV human glioblastoma xenograft - Control 54.3132770
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3183751
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7761962
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9256465
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0726967
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5057959
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7607463
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9394566
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0798567
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7733663